Navigation Links
FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisor Board
Date:6/11/2012

SAN DIEGO, June 11, 2012 /PRNewswire-iReach/ -- FirstMark, the diagnostic division of GenWay Biotech, announced today that Dr. Prediman K. (PK) Shah has joined it's Scientific Advisory Board.

Dr. Shah is Professor at Cedar Cedars-Sinai Professorial Series, and Director of the Division of Cardiology. He also is the Director of the Oppenheimer Atherosclerosis Research Center at Cedars-Sinai Medical Center where he leads several studies that focus on heart disease prevention and treatment. Dr. Shah holds the Shapell and Webb Family Chair in Clinical Cardiology at Cedars-Sinai. Dr. Shah has been Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA) since 1992. Between 1992 and 2005, Dr. Shah and his colleagues conducted revolutionary research on mutant apo-A1 protein, called Apo-A1 Milano that produced a form of HDL that provided greater protection against atherosclerosis and vascular inflammation. In separate studies conducted, Dr. Shah found that a vaccine created from LDL significantly reduced plaque buildup in animals that had high cholesterol levels.

"We are very pleased Dr. Shah has joined FirstMark's advisory team, " said Thomas Silberg, President and CEO of GenWay Biotech. "His outstanding background in cardiovascular medicine, his focus on prevention, and his extensive experience in research will be a critical support as we continue to build clinical interest and application for FirstMark PREvent."

Dr. Shah joins the FirstMark Scientific Advisory Board that is composed of innovative and nationally recognized leaders in cardiology and research. Each of these individuals has made substantial contributions to the field of cardiology. The main focus of the Board is to provide guidance for further clinical development and validation of FirstMark's new cardiovascular test PREvent. PREvent is the first and only multiple bioma
'/>"/>

SOURCE GenWay Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology news :

1. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
2. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
3. EMBO welcomes 55 leading life scientists as members
4. Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award
5. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
6. UC Santa Barbara researchers discover genetic link between visual pathways of hydras and humans
7. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
8. U of Alberta researcher steps closer to understand autoimmune diseases
9. Researchers attempt to solve problems of antibiotic resistance and bee deaths in one
10. UNH researchers find African farmers need better climate change data to improve farming practices
11. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... LA JOLLA, Calif. , Jan. 30, 2015 /PRNewswire/ ... realizes the great power and potential for genomic science ... to aid in disease prevention and treatment.  I was ... a potential new, government-funded precision medicine program. ... on advancing the science of genomics—from the first sequenced ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced ... Overview" report to their offering. , ... an individual is who she/he is claiming to be, and ... person,s unique physical characteristics, such as fingerprint, hand or palm ...
(Date:1/22/2015)... - Today, FindBiometrics, the leading source of biometrics industry news, interviews ... design. "When we launched FindBiometrics 12 years ago ... , founder and CEO of FindBiometrics. "Now it,s maturing very ... key players on a very broad scale.  We are known ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... extend a family should avoid using the cholesterol-lowering drugs ... that women who are pregnant should stop taking statins ... cholesterol is essential for normal fetal development. Indeed, ... in children of pregnant women using statins suggested that ...
... for HIV patients may be the best way of treating hepatitis ... A study of a protein called p7, has revealed that differences ... - known as genotypes - alter the sensitivity of the ... protein assists the spread of HCV around the body ...
... researchers from Penn State University and the University of Chicago ... particular virus, called N4, injects an unusual substance -- an ... bacterial cell. The results, which are published in the ... to improved understanding of the infection strategies used by viruses ...
Cached Biology News:Statin warning for pregnant women 2Leeds research points to new therapy for hepatitis C treatment 2Properties of unusual virus revealed in research 2Properties of unusual virus revealed in research 3
(Date:3/3/2015)... SAN DIEGO , March 3, 2015  Neurocrine ... that Kevin Gorman , President and Chief Executive ... Barclays Global Healthcare Conference in Miami.   ... at 10:15am ET (7:15am PT).  The presentation will be ... at http://www.neurocrine.com .   Listeners are ...
(Date:3/3/2015)... 2015 Adaptive Biotechnologies announced today that ... Board of Director as Chair of the Audit Committee. ... Chad oversees all finance, treasury and accounting functions. Since ... finance, treasury and accounting functions, and led the finance ... 2013, he was named Puget Sound Business Journal,s CFO ...
(Date:3/3/2015)... 03, 2015 Crown Bioscience, Inc., a ... launched a new Life Science division specializing in in ... , The first products released include in vivo ... soon to be released in vivo grade monoclonal antibodies ... expand their life science portfolio with additional antibody products ...
(Date:3/3/2015)... 3, 2015 Fried, Frank, Harris, Shriver & ... has joined the Firm as a partner in ... New York office. Mr. Lewis concentrates ... well as other intellectual property and general litigation. A ... represents both plaintiffs and defendants in a range of ...
Breaking Biology Technology:Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2Crown Bioscience Launches Life Science Product Catalog 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3
... first quarter 2008 stock ... repurchase program, BOSTON, April 30 ... image and information management,solutions, today reported unaudited financial results for the first ... ), Q1 Financial Highlights, Revenue: Total revenues for the ...
... LeMaitre,Vascular, Inc. (Nasdaq: LMAT ), a ... financial results for Q1 2008. Q1 2008,revenues were ... 2007., Q1 2008 revenues increased 5% in ... in its vascular category, while general,surgery revenues decreased ...
... New Step in the Company,s Global Branding Strategy, ... today announced the full integration of its Riedel-de ... May 1, 2008,( http://www.sigma-aldrich.com/rebranding )., "We have ... and,services," said Josef Zihlmann, Global Vice President of ...
Cached Biology Technology:AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 2AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 3AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 4AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 5AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 6AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 7AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 8AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 9AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 10AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 11LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 2LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 3LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 4LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 5LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 6LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 7LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 8LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 9LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 10LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 11Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands 2Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands 3
... are designed to rapidly and reliably amplify ... APA Technology. APAgene provides hassle-free, ready-to use ... necessary ingredients are provided in each kit. ... for gap filling, localized cloning of genomic ...
Rabbit polyclonal to Yaf9 ( Abpromise for all tested applications)....
... Bovine Calf Serum; U.S. ... seek an uncompromising quality; Low ... Collected from animals of US ... those who seek an uncompromising ...
...
Biology Products: